News | PET-CT | February 05, 2018

PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

Study findings could set the stage for multimodal image-guided fusion biopsy in the future

PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

February 5, 2018 — Using nuclear medicine, German researchers have found a way to accurately differentiate cancerous tissue from healthy tissue in prostate cancer patients. The research is highlighted in the February issue of The Journal of Nuclear Medicine.

According to the American Cancer Society, one in nine men will be diagnosed with prostate cancer in his lifetime. Early diagnosis is key to successful treatment.

The new study demonstrates that the maximum standardized uptake value (SUVmax) on Gallium-68 prostate specific membrane antigen (68Ga-PSMA) PET/CT scans correlates with PSMA-expression in primary prostate cancer. By this means, researchers were able to generate an SUVmax cutoff for the differentiation of cancerous and benign prostate tissue.

“To the best of our knowledge, this was the first study to generate a cutoff SUVmax, validated by immunohistochemistry, for separating prostate cancer from normal prostate tissue by 68Ga-PSMA PET/CT [positron emission tomography/computed tomography] images,” explained Vikas Prasad, M.D., Ph.D., of Charité Universitätsmedizin Berlin in Germany. “Our SUVmax cutoff can be used to confirm or rule out prostate cancer with a very high degree of sensitivity and specificity.”

He pointed out, “Recent years have brought tremendous advances in image-based biopsy of the prostate. However, in many patients, histopathology may not yield correct diagnosis (e.g., if the tumor is missed during true-cut biopsy). This is especially true for multifocal prostate cancer, less aggressive tumors, and cases of prostatitis or prior prostate irradiation, where MRI [magnetic resonance imaging] alone may not give the correct localization and malignancy grade.”

For the study, the data of 31 men (mean age of 67.2 years) who had undergone prostatectomies and preoperative PET scans were analyzed, with the SUVmax generated for suspicious areas and visually normal tissue. Both cancerous and benign prostate tissue samples (62 total) were stained with monoclonal anti-PSMA antibody. All the cancerous lesions could be confirmed histopathologically. The best cut-off value was determined to be 3.15 (sensitivity 97 percent, specificity 90 percent).

Prasad noted, “This validated cutoff of 3.15 for SUVmax enables the diagnosis of prostate cancer with a high sensitivity and specificity in both unifocal and multifocal disease.”

Looking ahead, he posited, “With advancement of image-registration/segmentation software and PET/MRI scanners, it is quite logical to predict that in the future PET images and SUVmax on a suspicious lesion in the prostate will be used for multimodal image-guided fusion biopsy.”

For more information: www.jnm.snmjournals.org

 

Related Content

Shorter Radiotherapy Courses Safe and Effective for Prostate Cancer
News | Prostate Cancer | April 23, 2018
Radiotherapy given in high doses over a shorter period of time is safe and effective for prostate cancer patients,...
Chest X-ray AI Algorithm Correctly Identifies Lung Disease for Dubai Health Authority
Feature | Artificial Intelligence | April 17, 2018
The Dubai Health Authority (DHA) announced the preliminary results of a chest X-ray artificial intelligence (AI)...
Novel PET Agent Could Help Guide Therapy for Brain Diseases

Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland

News | PET Imaging | April 10, 2018
Researchers have developed a new imaging agent that could help guide and assess treatments for people with various...
First Patient Treated in Online Adaptive Radiotherapy Trial With CyberKnife System
News | Stereotactic Body Radiation Therapy (SBRT) | April 06, 2018
Accuray Inc. and Erasmus MC announced the first patient has been successfully treated using an online-adaptive (OA)...
News | Oncology Diagnostics | April 05, 2018
April 5, 2018 — Myriad Genetic Laboratories Inc.
Diagnosing Breast Cancer Using Red Light

Schematic diagram for OM instrument: Seven pulsed lasers sequentially illuminate the compressed breast; transmitted light is detected by the 8-channel SiPM probe and the TDC acquires the signal. Credit: Edoardo Ferocino

News | Breast Imaging | April 02, 2018
Optical mammography (OM), which uses harmless red or infrared light, has been developed for use in conjunction with X-...
News | Endoscopes | April 02, 2018
Results from a recent prospective trial found the Wide Area Transepithelial Sampling with 3D Tissue Analysis (WATS3D)...
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
Edwards Completes Enrollment in PARTNER 3 Low-Risk CT Sub-Study
News | Computed Tomography (CT) | March 27, 2018
March 27, 2018 — Edwards Lifesciences Corp.
Combination Radiotherapy Beneficial in Treating Prostate Cancer
News | Prostate Cancer | March 27, 2018
March 27, 2018 — While there are many treatment options for men with...
Overlay Init